The specific pairing of estrogens and progestins in a combined oral contraceptive (COC) meaningfully shapes tolerability. In practice, continuation depends less on efficacy than on lived experience, particularly in terms of bleeding patterns, mood stability, and sexual well-being. Most side effects are mild and often settle with continued use or a switch to an alternative formulation. Because tolerability reflects the combined action of both components, differences can be attributed to the estrogen only when the progestin is held constant (e.g., estetrol/drospirenone [E4/DRSP] versus ethinylestradiol/drospirenone [EE/DRSP].

This section reviews common COC side effects through a “tolerability triad” lens: bleeding, mood, and sexual health, and considers cultural context. Estrogens modulate neurotransmitter pathways (notably serotonin and dopamine) implicated in mood; natural, body-identical estrogens such as estradiol/estradiol valerate (E2/E2V) and E4 are associated with steadier mood, more acceptable bleeding patterns and better sexual comfort than EE in many users. Because mood and expectations shape symptom perception, aligning counselling with patient priorities, planning an early follow-up, and switching promptly when needed are central to real-world tolerability and persistence.